GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Net Interest Income (for Banks)

3SBio (TRSBF) Net Interest Income (for Banks)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


3SBio (TRSBF) Business Description

Industry
Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.